Section Arrow
Quote
MDGL.NASDAQ
- Madrigal Pharmaceuticals
Quotes are at least 15-min delayed:2025/06/03 22:55 EDT
Last
 284.41
+11.74 (+4.31%)
Day High 
285.14 
Prev. Close
272.67 
1-M High
318.27 
Volume 
405.10K 
Bid
277
Ask
285
Day Low
268.69 
Open
271.99 
1-M Low
265 
Market Cap 
6.05B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 276.19 
20-SMA 285.91 
50-SMA 307.74 
52-W High 377.46 
52-W Low 200.63 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.84/3.39
Enterprise Value
6.17B
Balance Sheet
Book Value Per Share
32.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
180.13M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed：2025/06/03 22:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.